All In Biotech

Drug Trial Radar · NCT06707194

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis: a Multicenter Randomized Controlled Clinical Study

Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Jun 14, 2025

Primary completion

Mar 1, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to verify the clinical feasibility of Benzathine penicillin (BPG) /Etanercept (ETN) combination regimen in patients with spondyloarthritis (SpA) and at the same time compare Benzathine penicillin /Etanercept combination regimen and Etanercept maintenance therapy in reducing disease activity, improving patients' clinical symptoms and body function scores, enhancing quality of life, improving imaging performance and safety.

Conditions

  • Spondyloarthritis (SpA)
  • Ankylosing Spondylitis (AS)

Interventions

  • EtanerceptBiological

    Prefilled syringe, 25mg of hypodermic injection, twice a week

  • Benzathine PenicillinDrug

    Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks

  • PlaceboOther

    Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, intramuscular injection, once every two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient ASAS40 remission rate after 12 weeks of patient medicationTime frame: Week 12

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Nan Fang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Nan Fang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Inner Mongolia People's Hospital

    Hohhot, Inner Mongolia, China · Not yet recruiting

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.